DBV Technologies vs Marker Therapeutics
DBV Technologies is the larger business, with $5.6m of revenue in fiscal 2025 against $3.5m for Marker Therapeutics (1.6 times as much). DBV Technologies grew faster (35.8% against -46.2%). Marker Therapeutics kept more of each dollar of sales as profit: a net margin of -343.0% against -2607.3%. DBV Technologies carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | DBV TechnologiesDBVT, 2025 | Marker TherapeuticsMRKR, 2025 |
|---|---|---|
| Revenue | $5.6m | $3.5m |
| Revenue growth | 35.8% | -46.2% |
| Net income | −$147m | −$12.2m |
| Operating margin | -2609.2% | -363.5% |
| Net margin | -2607.3% | -343.0% |
| Return on equity | -149.8% | -68.8% |
| Free cash flow | −$122m | −$12.0m |
| Cash | $194m | $16.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 125 | 5 |
| Market value | $4.60bn | $16.5m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 7 sales | 0 buys, 0 sales |